Circurna was founded to address fundamental limitations of linear mRNA technologies, including short-lived protein expression, systemic reactogenicity, dependence on ultra-cold-chain logistics, and restricted delivery formats. These constraints limit how broadly current RNA therapeutics can be deployed and who can benefit from them.
Through its proprietary ciRNA™ circular RNA platform, we engineer next-generation RNA therapeutics with precision targeting for transformative impact across multiple disease areas. By redesigning the RNA molecule itself, the lipid nanoparticle (LNP) formulation and introducing a patch delivery system, Circurna is building a platform capable of delivering robust and sustained therapeutic protein expression with improved tolerability, simplified global distribution, and injection-free patient-friendly administration, addressing the core limitations of earlier RNA technologies.
Circurna’s proprietary ciRNA™ platform is based on circular RNA, a structural format designed for increased stability and sustained protein expression in target cells, lowering dose and administration frequency.
The platform is designed to support multiple therapeutic modalities and delivery approaches within a single, consistent technology framework.
Circurna is advancing a circular RNA platform designed for durability, safety, and real-world delivery.
We welcome engagement from investors, partners, and collaborators.
